-
1 Comment
BrightPath Biotherapeutics Co., Ltd is currently in a long term downtrend where the price is trading 9.0% below its 200 day moving average.
From a valuation standpoint, the stock is 1215.2% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 927.5.
BrightPath Biotherapeutics Co., Ltd's total revenue sank by 49.4% to $425K since the same quarter in the previous year.
Its net income has dropped by 0.7% to $-504M since the same quarter in the previous year.
Based on the above factors, BrightPath Biotherapeutics Co., Ltd gets an overall score of 0/5.
| Exchange | TSE |
|---|---|
| CurrencyCode | JPY |
| ISIN | JP3274140007 |
| Sector | Healthcare |
| Industry | Biotechnology |
| PE Ratio | None |
|---|---|
| Target Price | None |
| Beta | 1.35 |
| Market Cap | 4B |
| Dividend Yield | None |
BrightPath Biotherapeutics Co., Ltd. engages in the development of cancer immunotherapy drugs in Japan. It is developing GRN-1201, a cancer peptide vaccine candidate that is in Phase II clinical trials for the treatment of non-small cell lung cancer, as well as in Phase I clinical trials to treat melanoma. The company is also developing BP2201, a product candidate in Phase I clinical trials to target cancer antigens in various types of cancer; and BP2301, a product candidate in Phase I clinical trials for the treatment of solid tumors sarcoma and gynecological cancers. In addition, its product candidates in preclinical trials include BP1202 that targets CD39; BP1210, which suppresses T cell cytotoxicity; BP1212 to inhibit TIM-3 and CD39; BP1209 to target tumor-specific neoantigens; and BP1200 to target CD73. The company was formerly known as GreenPeptide Co., Ltd. and changed its name to BrightPath Biotherapeutics Co., Ltd. in July 2017. BrightPath Biotherapeutics Co., Ltd. was incorporated in 2003 and is headquartered in Tokyo, Japan.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 4594.TSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
